Detailed Notes on M3541
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To guage several intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Most important trial targets were To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis